Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report

The clinical efficacy of current therapies for Hepatocellular carcinoma (HCC) are unsatisfactory. In recent years, chimeric antigen receptor (CAR) T-cell therapies have been developed for solid tumors including advanced HCC (aHCC), but limited progress has been made. Glypican-3 is a promising immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Hongwei, Xing, Chongyun, Jiang, Songfu, Yu, Kang, Dai, Shengjie, Kong, Hongru, Jin, Yuepeng, Shan, Yunfeng, Yang, Wenjun, Wang, Zhen, Xiao, Jun, Wang, Huamao, Wang, Wei, Li, Zonghai, Shi, Keqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428446/
https://www.ncbi.nlm.nih.gov/pubmed/36059488
http://dx.doi.org/10.3389/fimmu.2022.963031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428446/
https://www.ncbi.nlm.nih.gov/pubmed/36059488
http://dx.doi.org/10.3389/fimmu.2022.963031

Ejemplares similares